Sionna Therapeutics, Inc.
3.60USD
-0.2000 (-5.26%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on SION.
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| FY | — | — | — | 0.0 | 0.0 |
| Q1 | — | — | — | — | — |
| Q2 | — | — | — | — | — |
| Q3 | — | — | — | 0.0 | — |
| Q4 | — | — | — | 0.0 | — |
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| FY | — | -1.60 | -1.88 | -2.45 | -2.23 |
| Q1 | — | -384.00 | -.620 | -.600 | — |
| Q2 | — | -271.00 | -.410 | -.660 | — |
| Q3 | — | -.567 | -.460 | -.677 | — |
| Q4 | — | -.411* | -.511* | -.551 | — |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
Debt level and coverage